Internal Medicine, Rheumatology · Bend, OR
NPI
1558686352
Since 2010
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
1501 NE Medical Center Dr
Bend, OR, 97701
Phone (541) 382-2811
Groups this clinician bills Medicare through
Medicare paid, 2024
$3.6M
222,899 services
Medicare patients, 2024
1,112
Average age 75
Drug cost, 2024
$2.9M
3,562 prescriptions
Company payments, 2025
$175
From 1 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Anthony M Kahr was code J3262 (injection, tocilizumab, 1 mg), 47,110 times for 18 patients. In total Anthony M Kahr billed 222,899 services in 108 codes, and Medicare paid $3.6M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-04-02.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J3262 Injection, tocilizumab, 1 mg | Office | 47,110 | 18 | $4.70 | $221K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 33,390 | 36 | $8.54 | $285K |
| J3380 Injection, vedolizumab, intravenous, 1 mg | Office | 23,700 | 19 | $17.40 | $412K |
| J0897 Injection, denosumab, 1 mg | Office | 19,140 | 241 | $20.35 | $390K |
| J2350 Injection, ocrelizumab, 1 mg | Office | 13,800 | 17 | $42.56 | $587K |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 8,780 | 55 | $25.01 | $220K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 8,075 | 23 | $33.27 | $269K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 7,250 | 20 | $8.81 | $64K |
| Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg | Office | 4,600 | 28 | $31.62 | $145K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 1,040 | 208 | $4.78 | $4,973 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 800 | 44 | $0.09 | $71.59 |
| 99214 Office E&M - Established | Office | 751 | 452 | $90.16 | $68K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 724 | 20 | $0.10 | $75.51 |
| 96372 Injection Administration | Office | 708 | 288 | $11.00 | $7,790 |
| 36415 Venipuncture Blood Collection | Office | 686 | 437 | $8.61 | $5,907 |
By year: 2022 $2.8M for 154,072 services; 2023 $3.2M for 193,925 services; 2024 $3.6M for 222,899 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 686 | 437 | $8.61 | $5,907 |
| 85025 Blood Count | 439 | 272 | $7.56 | $3,317 |
| 86140 Clinical Chemistry | 416 | 266 | $5.04 | $2,098 |
| 82565 Clinical Chemistry | 388 | 270 | $4.99 | $1,936 |
| 85652 Clinical Chemistry | 340 | 224 | $2.63 | $895 |
| 80076 Clinical Chemistry | 267 | 159 | $7.94 | $2,120 |
| 82306 Clinical Chemistry | 234 | 197 | $28.92 | $6,766 |
| 82310 Clinical Chemistry | 166 | 141 | $5.04 | $836 |
| 80053 Clinical Chemistry | 148 | 111 | $10.35 | $1,532 |
| 82040 Clinical Chemistry | 115 | 98 | $4.85 | $558 |
Medicare prescription drug claims, 2024
In 2024, the drug Anthony M Kahr prescribed most often to Medicare patients was Hydroxychloroquine Sulfate, with 554 prescriptions and refills. In total Anthony M Kahr wrote 3,562 Medicare prescriptions that cost $2.9M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Hydroxychloroquine Sulfate Generic | 554 | 1,046 | 142 | $26K |
| Methotrexate Methotrexate Sodium | 532 | 947 | 139 | $18K |
| Prednisone Generic | 520 | 827 | 161 | $4,588 |
| Allopurinol Generic | 226 | 636 | 58 | $3,528 |
| Alendronate Sodium Generic | 208 | 571 | 83 | $1,837 |
| Gabapentin Generic | 104 | 188 | 29 | $1,334 |
| Humira(Cf) Pen Adalimumab | 101 | 107 | 12 | $749K |
| Meloxicam Generic | 101 | 166 | 27 | $835 |
| Humira(Cf) Adalimumab | 89 | 89 | Under 11 | $624K |
| Leflunomide Generic | 81 | 176 | 23 | $6,051 |
| Mycophenolate Mofetil Generic | 66 | 110 | 18 | $8,959 |
| Tramadol Hcl Generic | 64 | 65 | 13 | $586 |
| Sulfasalazine Dr Sulfasalazine | 62 | 83 | 15 | $2,646 |
| Duloxetine Hcl Generic | 45 | 79 | 13 | $1,068 |
| Cyclobenzaprine Hcl Generic | 40 | 56 | 11 | $629 |
Brand drugs: - claims; generic drugs: 2,960 claims; opioid claims: 65.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Anthony M Kahr $175 ($175 in general payments such as food, travel and fees) from 1 company. The largest payer was Amgen Inc. with $175.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 1 | $175 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.